Recent developments in second and third line therapy of metastatic renal cell carcinoma

Expert Rev Anticancer Ther. 2016 May;16(5):469-71. doi: 10.1586/14737140.2016.1168696. Epub 2016 Mar 31.
No abstract available

Keywords: Cabozantinib; government funding; metastatic; nivolumab; renal cell cancer; second line; therapy; third line.

Publication types

  • Editorial

MeSH terms

  • Antineoplastic Agents / administration & dosage*
  • Carcinoma, Renal Cell / drug therapy*
  • Carcinoma, Renal Cell / pathology
  • Humans
  • Kidney Neoplasms / drug therapy*
  • Kidney Neoplasms / pathology
  • Neoplasm Metastasis

Substances

  • Antineoplastic Agents